Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bolt Biotherapeutics Inc (BOLT)

Bolt Biotherapeutics Inc (BOLT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,108
  • Shares Outstanding, K 38,273
  • Annual Sales, $ 7,880 K
  • Annual Income, $ -69,200 K
  • EBIT $ -76 M
  • EBITDA $ -79 M
  • 60-Month Beta 0.92
  • Price/Sales 3.06
  • Price/Cash Flow N/A
  • Price/Book 0.30
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.71
  • Most Recent Earnings $-0.40 on 11/12/24
  • Next Earnings Date 11/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.38
  • Number of Estimates 3
  • High Estimate -0.34
  • Low Estimate -0.41
  • Prior Year -0.47
  • Growth Rate Est. (year over year) +19.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5400 +15.93%
on 11/19/24
0.7000 -10.57%
on 10/28/24
-0.0533 (-7.85%)
since 10/25/24
3-Month
0.5400 +15.93%
on 11/19/24
0.7180 -12.81%
on 10/25/24
-0.0639 (-9.26%)
since 08/27/24
52-Week
0.5400 +15.93%
on 11/19/24
1.5600 -59.87%
on 04/01/24
-0.3039 (-32.68%)
since 11/27/23

Most Recent Stories

More News
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

– BDC-1001 monotherapy and combination dose-escalation portion of the trial in HER2-expressing solid tumors on track to complete this year– New portfolio...

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022

- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present - REDWOOD CITY, Calif., May 27, 2022 (GLOBE...

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

–   BDC-1001 monotherapy and OPDIVO® combination trials progressing toward data readouts in second half of 2022 –   Cash balance of $246.8 million...

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference

REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new...

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights

BDC-1001 for the treatment of patients with HER2-expressing solid tumors on track for recommended Phase 2 dose identification later in 2022; BDC-1001...

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022

REDWOOD CITY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new...

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021

Company to continue monotherapy dose-escalation and evaluate weekly dose regimen Combination dose-escalation study of BDC-1001 with Opdivo® on target to...

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021

REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a...

BOLT : 0.6260 (-0.62%)

Business Summary

Bolt Biotherapeutics Inc. is a clinical-stage immuno-oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company's principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California.

See More

Key Turning Points

3rd Resistance Point 0.6839
2nd Resistance Point 0.6619
1st Resistance Point 0.6440
Last Price 0.6260
1st Support Level 0.6041
2nd Support Level 0.5821
3rd Support Level 0.5642

See More

52-Week High 1.5600
Fibonacci 61.8% 1.1704
Fibonacci 50% 1.0500
Fibonacci 38.2% 0.9296
Last Price 0.6260
52-Week Low 0.5400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar